US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Latest News about NASH

Recent news which mentions NASH

VettaFi Voices On: One Year as VettaFi
Tags research ETFs Morris
From ETF Trends
CBG: The 'Mother Cannabinoid' May Hold Key To Treating Nonalcoholic Fatty Liver Disease Symptoms
Tickers CBG
Tags MDPI nonalcoholic fatty liver disease Shelby McDaniel
From Benzinga
Lipocine Meets Resolution Regulatory Endpoint In Mid-Stage NASH Trial
Tickers LPCN
Tags Trading Ideas Health Care Penny Stocks
From Benzinga
CohBar Stock Edges Higher As Mitochondria Based Therapeutic Shows Encouraging Action In Early-Stage NASH Trial
Tickers CWBR
Tags Market News Biotech Briefs
From Benzinga
Galmed Stock Jumps As FDA Signs Off Use Of Aramchol Meglumine In Late Stage NASH Trial
Tickers GLMD
Tags Phase 3 Trial GLMD Penny Stocks
From Benzinga
Theratechnologies In Search Of Potential Partner For Late-Stage NASH Study Of Tesamorelin, Reports Q2 Earnings
Tickers THTX
Tags Small Cap General NASH
From Benzinga
CohBar Stock Slumps As Data From NASH, Obesity Candidate Delayed By Almost Two Months
Tickers CWBR
Tags CWBR Biotech Penny Stocks
From Benzinga
Hepion Pharma's NASH Candidate Aces Mid-Stage Study
Tickers HEPA
Tags HEPA Biotech Market News
From Benzinga
Akero's NASH Candidate Shows Substantial Liver Fat Reductions After Four Months Of Treatment
Tickers AKRO
Tags NASH AKRO Briefs
From Benzinga